I'm LongbridgeAI, I can summarize articles.HSBC Research predicts 2026 as a harvest year for China's innovative drug out-licensing, citing USD125 billion in deal value by August 2026. Attributing resilience to policy support and global pharma demand, HSBC maintains Buy ratings on Hansoh Pharma, SKB Bio, Innovent Bio, Akeso, and Keymed Bio-B with specific target prices.
Despite mounting US interest rates, China's biopharmaceutical sector remained resilient in late September across the Hong Kong and mainland China markets, supported by policy measures and prospects for out-licensing, HSBC Global Investment Research said in a report.
2026 will be a harvest year for China's innovative drug out-licensing, the broker said. In 8M26, the value of China's out-licensing deals whopped USD125 billion, accounting for about 62% of global deal value. The broker believed China's innovative drugs are attractive to global major pharmaceutical companies facing patent cliff pressure from 2026 to 2035, thanks to advantages in R&D costs, competitive landscape and clinical efficacy.
The broker upheld Buy ratings on HANSOH PHARMA (03692.HK) -0.340 (-1.004%) Short selling $20.50M; Ratio 44.324% , SKB BIO (06990.HK) +1.000 (+0.215%) Short selling $6.26M; Ratio 21.328% , INNOVENT BIO (01801.HK) -0.100 (-0.100%) Short selling $67.29M; Ratio 48.787% , AKESO (09926.HK) -0.350 (-0.373%) Short selling $69.98M; Ratio 44.865% and KEYMED BIO-B (02162.HK) +0.900 (+1.215%) Short selling $2.71M; Ratio 13.617% , with target prices of HKD49.5, HKD584, HKD130, HKD163 and HKD107, respectively. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-09-25 12:25.)